May 12th 2024
Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Bayer Suspends Production of Radium-223 Due to Manufacturing Problem
October 16th 2014Production of the prostate cancer drug radium-223 (Xofigo) has been suspended indefinitely by its maker, Bayer HealthCare Pharmaceuticals, due to a manufacturing problem. The company confirmed the manufacturing suspension in a statement released to Targeted Oncology.
Read More
Q & A With Emmanuel S. Antonarakis, MBBCh: AR-V7 and Resistance to AR-Targeting Agents
October 7th 2014To gain further insight into AR-V7 and resistance to AR-targeting agents, Targeted Oncology interviewed the lead author, Emmanuel S. Antonarakis, MBBCh, an assistant professor at Johns Hopkins Medicine.
Read More
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
October 1st 2014Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses the results of a trial that examined AR-V7 and resistance to enzalutamide and abiraterone in patients with prostate cancer.
Read More
Abbreviated Course of ADT + RT Produces Similar Outcomes, Improves QoL in High-Risk Prostate Cancer
September 17th 2014When given along with radiation therapy to men with high-risk prostate cancer, 18 months of androgen-deprivation therapy (ADT)—as opposed to a 36-month course—not only generates similar long-term outcomes, but results in a better quality of life.
Read More
Pembrolizumab Combination to be Evaluated in Prostate Cancer
August 28th 2014Advaxis and Merck have entered into a clinical trial collaboration agreement to evaluate the combination of two novel immunotherapies for the treatment of patients with metastatic castration-resistant prostate cancer.
Read More
Improving the Cure Rate and the Burden of Cure in Prostate Cancer
August 15th 2014Lawrence H. Einhorn, MD, distinguished professor of medicine, division of hematology/oncology, Indiana University School of Medicine, Giant of Cancer Care: Genitourinary Cancer, discusses new methods being explored to help improve the cure rate in prostate cancer.
Watch
Analysis of a Phase II Study of Cabozantinib in mCRPC
July 15th 2014Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.
Watch
14-Month Survival Benefit Demonstrated With Adding Chemo to ADT in Prostate Cancer
June 3rd 2014In what was described as “an almost unprecedented improvement in median survival,†the addition of the chemotherapy drug docetaxel to standard hormone therapy prolonged life for men with newly diagnosed metastatic, hormone-sensitive prostate cancer by nearly 14 months.
Read More
The Adoption of Robot-Assisted Surgery for Prostate Cancer
May 28th 2014Scott Eggener, MD, associate professor of surgery, co-director, Prostate Cancer Program, director, Translational and Outcomes Research, Section of Urology, University of Chicago, discusses the adoption of robot-assisted surgery and its impact on treatment patterns for newly diagnosed localized prostate cancer patients.
Watch
Validation of a 46-Gene CCP RNA Signature for Predicting Prostate Cancer Death
May 21st 2014Peter T. Scardino, MD, FACS, discusses an analysis presented at the 2014 AUA Annual Meeting: Validation of a 46-gene cell cycle progression (CCP) RNA signature for predicting prostate cancer death in a conservatively managed watchful waiting needle biopsy cohort.
Watch
Study Suggests Delaying ADT Until Symptoms Appear Following Primary Prostate Cancer Treatment
May 15th 2014A rising prostate-specific antigen (PSA) after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy (ADT), a large observational study has found.
Read More